Third MMR dose offers extended protection against mumps

  • Patricia K & al.
  • J Infect Dis
  • 23 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A third dose of measles-mumps-rubella (MMR) vaccine increases antibody levels in young adults and may protect against mumps for longer periods of time than previously believed.

Why this matters

  • Findings bolster Advisory Committee on Immunization Practices recommendations for at-risk persons during outbreaks.
  • MMR booster might also boost waning immunity for up to 1 year.

Key results

  • 134 participants; age, 18-25 years.
  • With IgG cutoff of 102 RU/mL, 80.9% of participants were protected prebooster, increasing to 93.9% 4 weeks postbooster (P=.001), leveling off at 91.3% at 1 year (P=.026).
  • Roughly 77.6% had immunity (ND50 titer>34) against mumps prebooster, increasing to 85.7% (P<.0001 at weeks year respectively.>
  • For outbreak strain specifically (ND50 titer>26), 78.2% were protected prebooster, increasing to 88.4% (P=.001), 88.8% (P<.0001 weeks year respectively.>

Study design

  • Prospective, interventional Dutch study assessing the value of third MMR vaccine dose to boost immunity in outbreak scenarios.
  • Funding: Dutch Ministry of Health, Welfare and Sport.

Limitations

  • Discrimination bias.
  • Vaccine schedule differs from U.S.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit